赜灵生物

Zeling Biopharma is a clinical-stage biopharmaceutical company headquartered in Chengdu, China, specializing in the development of innovative small molecule drugs. Founded by Academician Chen Fen'er, the company focuses on therapeutic areas with significant unmet medical needs, including oncology, the central nervous system, and autoimmune diseases. Its pipeline features several promising candidates, such as ZL-82, a JAK inhibitor for myelofibrosis, and ZL-01, a GABA-A receptor modulator for postpartum depression. Zeling Biopharma integrates advanced medicinal chemistry with efficient clinical translation to advance its diverse portfolio of novel therapeutics. The company leverages its proprietary discovery platform to identify high-quality lead compounds for challenging biological targets.